← All indications
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
Subtype terms (6)
More specific conditions that are subtypes of Asthma in the MeSH hierarchy.
- Asthma, Aspirin-Induced
6 drugs (5 approved, 1 experimental)
- Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome
13 drugs (9 approved, 4 experimental)
- Asthma, Exercise-Induced
17 drugs (13 approved, 4 experimental)
- Asthma, Occupational
1 drug experimental
- Cough-Variant Asthma
- Status Asthmaticus
17 drugs (16 approved, 1 experimental)
Drugs by status
Approved for this indication (60)
- arformoterol
- tiotropium
- albuterol
- aminophylline
- oxtriphylline
- triamcinolone
- apricot
- cromoglicic acid
- reslizumab
- pirbuterol
- zileuton
- fenoterol
- su-huang
- fluticasone
- diphemanil methylsulfate
- metaproterenol
- budesonide
- omalizumab
- nedocromil
- methylprednisolone
- menthol
- urea
- formoterol
- flunisolide
- comarum palustre
- tezepelumab
- mometasone
- tulobuterol
- betamethasone
- montelukast
- +30 more
Phase 4 trials (81)
- bupropion
- bilastine
- buspirone
- desloratadine
- adenosine monophosphate
- propranolol
- prasugrel
- quetiapine
- valproic acid
- erythromycin
- lysozyme
- magnesium sulfate
- lansoprazole
- escitalopram
- phenytoin
- lithium
- cisatracurium
- remifentanil
- immunovac
- indacaterol
- house dust mite allergen
- calcifediol
- glycopyrronium
- venlafaxine
- azelastine
- regadenoson
- Azoximer
- lamotrigine
- sufentanil
- inactivated influenza vaccine
- +51 more
Phase 3 trials (74)
- zinc sulfate
- sulfasalazine
- tivantinib
- roflumilast
- atorvastatin
- fentanyl
- masitinib
- ramelteon
- ibuprofen
- polyphenols
- levocarnitine
- shr-1905
- ketamine
- colchicine
- sitagliptin
- sweet vernal, orchard, perennial rye, timothy, and kentucky blue grass mixed pollens allergen extract
- t521
- loratadine
- umeclidinium
- 610
- Streptococcus thermophilus
- saccharomyces boulardii
- water
- timothy grass pollen allergen extract
- corn
- reuterin
- naltrexone
- Doxofylline
- lactobacillus delbrueckii
- miglyol oil
- +44 more
Phase 2 trials (250)
Phase 1 trials (102)
- bedaquiline
- laninamivir octanoate hydrate
- nitrosoglutathione
- vr942
- rv16ub
- bi 144807
- gw597901x
- carbidopa
- zavegepant
- alprazolam
- butylhydroxytoluene
- hyperpolarized helium
- bi 1021958
- pur003
- alpha sprout homogenate
- endotoxin
- hbm9378
- mk-8351
- tqc2938
- birch allergen
- cc-93538
- litapiprant
- medicinal charcoal
- gsk-2269557
- ginger
- rv1729
- ketoconazole
- 9mw1911
- apg777
- pf-03893787
- +72 more
Other trials (55)
- huangqi guizhi wuwu
- caffeine
- andosan
- stanols
- capsaicin
- ma-hsing-kan-shih-tang
- citalopram
- bifiasthm
- fkbp51
- dextrothyroxine
- thenyldiamine
- glycerin
- citric acid
- magnesium
- liu-jur-zi-tang
- zanamivir
- nicotine
- plant stanol
- magnesium hydroxide
- alfalfa
- canola oil
- huangqi
- helium
- orange juice
- helium-3
- huangkui
- human fecal microbiota
- pimagedine
- cd4cd8aa
- lactobacillus reuteri
- +25 more
Organizations
Organization Involved with Phase 4 Indications (236)
- Firestone Institute for Respiratory Health
- Otsuka
- Ajou University
- National Institutes of Health (NIH)
- National University of Ireland
- University of Ferrara
- Northwell Health
- Badalona Hospital Germans Trias i Pujol
- Kuala Lumpur General Hospital
- American Lung Association
- Newcastle University
- Johns Hopkins University
- Asthma Management Systems
- University Hospitals of North Midlands NHS Trust
- University of Turku
- Lund University
- AAADRS Clinical Research Center
- Queen's University, Belfast
- University of Montreal
- Karolinska Institute
- Hospital Universitario Central de Asturias
- Barts & The London NHS Trust
- Boston University
- Eisai
- National Children's Research Centre
- Allergy and Asthma Center of El Paso
- Université catholique de Louvain
- Baqiyatallah Medical Sciences University
- University of Brighton
- Centers for Disease Control and Prevention (CDC)
- +206 more
Organization Involved with Phase 3 Indications (158)
- SkyePharma AG
- Janssen Pharmaceutica NV
- Allergy and Asthma center of North Carolina, PA, High Point
- Fudan University
- Aarhus University
- Hospital POLUSA, Lugo
- University of Texas, Galveston
- MAP Pharmaceuticals
- Mylan
- Actavis
- Mahidol University
- AB Science
- University of Modena and Reggio Emilia
- European Union
- Daiichi Sankyo
- Translational Research Institute for Metabolism and Diabetes, Florida
- Olmsted Medical Center
- SK Chemicals
- Hatyai Hospital
- Laval University
- Universidad Autonoma de Nuevo Leon
- Sun Pharmaceuticals
- Nycomed
- Pearl Therapeutics
- Cipla
- Thrasher Research Fund
- BECRO Ltd.
- MDS Pharma
- Abbott
- North Carolina Clinical Research
- +128 more
Organization Involved with Phase 2 Indications (170)
- Sylvana Research Associates
- RSPR Pharma AB
- MediciNova
- Pierre Fabre
- Theravance
- Optum
- University of Manchester
- Moorgreen Hospital, Southampton
- SickKids Foundation
- Pharmenterprises LLC
- Toledo Center for Clinical Research
- AbbVie
- Tuen Mun Hospital, Hong Kong
- Humboldt University
- Comac Medical
- Shanghai University of Traditional Chinese Medicine
- Array BioPharma
- University of Manitoba
- Concentrx Pharmaceuticals, Inc.
- University of Lodz
- Florida Atlantic University
- Foresee Pharmaceuticals Co., Ltd.
- Pharmaceutical Research Associates, Inc. (PRA)
- Axikin Pharmaceuticals, Inc.
- Sterna Biologicals GmbH & Co. KG
- Pivotal S.L.
- Alexion
- Government of Russia
- Zambon
- Verona Pharma plc
- +140 more
Organization Involved with Phase 1 Indications (38)
- PharmaKing
- Respirics Inc.
- Medigreen Biotechnology Corp.
- Government of Poland
- Revalesio Corporation
- TFF Pharmaceuticals
- Equillium
- Government of Taiwan
- Q-Pharm
- Pieris Pharmaceuticals GmbH
- RespiVert
- Biocon Limited
- Pulmatrix Inc.
- CSL Behring
- Palo Biofarma, S.L
- U-BIOPRED Consortium
- Lung Clinic Grosshansdorf Germany
- University of Monastir
- CRS Clinical Research Services Kiel GmbH
- TFF Pharmaceuticals, Inc.
- Accenture
- University of Montpellier
- Orion Corporation
- Afferent Pharmaceuticals
- Alexza Pharmaceuticals, Inc.
- Melbourne Health
- IDeA States Pediatric Clinical Trials Network
- Nuvaira, Inc.
- Hanmi Pharmaceutical
- CIM Sant Pau
- +8 more
Organization Involved with Other Experimental Indications (87)
- University of Nebraska
- Brown University
- National Children's Research Centre, Ireland
- Roma Paediatrics
- University of Chester
- Huazhong University of Science and Technology
- Scripps
- Clasado Biosciences
- State of New York
- The John van Geest Cancer Research Centre
- National Institute of Environmental Health Sciences (NIEHS)
- Sir T. General Hospital and Government Medical College
- Uppsala University
- Dalhousie University
- Cultural Foundation of Finland, Helsinki, Finland
- HOST Therabiomics
- Ostergotland County Council, Sweden
- Government of Dubai
- West-Ward Pharmaceutical
- Cognis
- Government Medical College, Bhavnagar
- University of Kansas
- Health Holland
- Government of Sweden
- American Academy of Pediatrics
- United Arab Emirates University
- The Regional Public Hospital in Lesko, Poland
- Belfast Health and Social Care Trust
- University of Nove de Julho
- The Ontario Thoracic Society of the Ontario Lung Association
- +57 more